Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2025 03:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients

NGM Bio announces first participant dosed in EMERALD Phase 2 clinical study of NGM120 for the treatment of hyperemesis gravidarum (HG).
February 04, 2025 07:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer

NGM Bio today announced the appointment of Wendy Yeh, M.D. as Chief Medical Officer.
December 19, 2024 07:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate

NGM Bio and KdT Ventures today announced the signing of a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-klotho agonist drug candidate.
July 17, 2024 07:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

The Column Group (TCG) led the round with participation from a select group of investorsPrimary sclerosing cholangitis (PSC) is a rare liver disease that irreparably damages the bile ducts, leading to...
April 05, 2024 09:19 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Closing of Tender Offer

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
March 19, 2024 17:30 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
March 11, 2024 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with...
February 26, 2024 09:03 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP

NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding...
February 20, 2024 16:01 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
January 17, 2024 16:47 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...